Medidata Opens Access to its Patient Insights Program

Enabling Sponsors and CROs to Leverage Proprietary Patient Centricity by Design Process for Clinical Trials

Medidata, a Dassault Systèmes company, today announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Centricity by Design process for clinical trials.

Medidata will open access to its Patient Insights Program as part of a new offering to incorporate a patient-centric approach to the design and development of clinical trial protocols and technologies.

The Patient Insights Program provides access to Medidata’s experienced and diverse Patient Insights Board, using innovative workshops called design studios to guide the creation of protocols and patient-facing solutions to improve clinical trial experiences, expedite clinical trial delivery timelines, and bring therapies to market faster.

“Medidata is the first company to institute a formal process of infusing the patient perspective into the software development life cycle to create technical solutions improving the overall patient experience,” said Alicia Staley, vice president, Patient Engagement at Medidata. “We are opening up access to this program to ultimately make clinical trials an option for more people, including those historically left behind by clinical trials.”

“Patient centricity” has been a buzzword for nearly a decade but most clinical studies are designed with little to no direct input from the patients/caregivers that are expected to enroll in and adhere to a clinical research study. Patient engagement has mostly been limited to sporadic and superficial sessions, with little impact on reducing patient burden or improving enrollment, retention, and experience.

“Participating in a Patient Design Studio with Medidata’s patient advocates to co-create, edit and inform our Clinical Trial Readiness Tool was invaluable,” said Erin Miller, development manager/ IMPACT and PATH Program liaison for Lazarex Cancer Foundation. “This one-of-a-kind tool will help us understand each patient’s individual journey and allow us to get them the resources they need to successfully stay in their clinical trial, giving them hope and a chance for an improved cancer health outcome.”

The Medidata Patient Insights team has run over 20 design studios to provide feedback and insights into Medidata’s products. Medidata’s Patient Centricity by Design is a formal methodology by which the patient perspective is infused into the software development life cycle. This video shows how Medidata develops empathetic technical solutions by including patients in our work.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

SourceMedidata

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”